[1] ROSENSTEIN R,HOUGH A.Empagliflozin,cardiovascular outcomes,and mortality in type 2 diabetes[J].N Engl J Med,2016,373(22):2117-2128.
[2] VIONNET N,HANI E H,DUPONT S,et al.Genomewide search for type 2 diabetes-susceptibility genes in French whites:evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24[J].Am J Human Genet,2017,67(6):1470-1480.
[3] RUBINO F,NATHAN D M,ECKEL R H,et al.Metabolic surgery in the treatment algorithm for type 2 diabetes:a joint statement by International Diabetes Organizations[J].Obes Surg,2016,12(6):1144-1162.
[4] MARSO S P,BAIN S C,CONSOLI A,et al.Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J].N Engl J Med,2016,375(19):1834-1844.
[5] 代丹丹,周春山,张俨.广州市中产阶层的特征及影响因素研究——基于马斯洛需求层次理论的实证分析[J].世界地理研究,2016,25(1):137-150.
[6] 常红,宋海庆,乔雨晨,等.以马斯洛需求层次论为基础的高职护生临床实习需求调查研究[J].北京医学,2016,38(5):494-495.
[7] 中国2型糖尿病防治指南(2013年版)[J].中国糖尿病杂志,2014,8(22):2-42.
[8] 华丽,朱伟萍.中文版《糖尿病自我管理行为量表》的信效度验证[J].解放军护理杂志,2014,31(16):5-8.
[9] MARSO S P,BAIN S C,CONSOLI A,et al.Semaglutide and cardiovascular outcomes in patients with type 2 Diabetes[J].N Engl J Med,2016,375(19):1834-1844.
[10] NEAL B,PERKOVIC V,MAHAFFEY K W,et al.Canagliflozin and cardiovascular and renal events in type 2 diabetes[J].N Engl J Med,2017,377(7):644-657.
[11] FITCHETT D,ZINMAN B,WANNER C,et al.Editor's choice:fast track:heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk:results of the EMPA-REG OUTCOME® trial[J].Eur Heart J,2016,37(19):1526-1534.
[12] PERSSON M,CNATTINGIUS S,WIKSTRÖM A K,et al.Maternal overweight and obesity and risk of pre-eclampsia in women with type 1 diabetes or type 2 diabetes[J].Diabetologia,2016,59(10):2099-2105.
[13] 周艺琳,周参新.基于需要理论的层级护理方案在血液透析患者中的效果研究[J].中华全科医学,2017,15(7):1256-1258.
[14] 王月会.层级培训模式对护士理论操作水平及护理质量的影响[J/OL].临床医药文献电子杂志,2016,3(59):11816-11817.
[15] 李虹.马斯洛需要层次理论在门急诊输液护理中应用[J].中西医结合护理(中英文),2017,3(6):177-178. |